IDEXX LABORATORIES INC /DE News
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
see moreIDEXX LABORATORIES INC /DE Market News
6h
IDEXX Laboratories Delivers Strong Q3 Results, Raises Full‑Year Guidance, Stock Soars
- IDEXX reports third‑quarter revenue of $1.214 billion (+10% organic), EPS of $4.01 (+18%), raises 2026 outlook as stock jumps over 20%.
14d
IDEXX Laboratories Gears Up for Q3 Earnings as Diagnostic Innovations Drive Momentum
IDEXX Laboratories (NASDAQ: IDXX) will report Q3 2026 results soon, with recent diagnostic upgrades and in‑clinic testing expansions positioning the stock for renewed investor focus.
28d
IDEXX Laboratories Sets Q3 2026 Earnings Date, Continues Diagnostic Expansion Ahead of Report
IDEXX schedules Q3 2026 earnings release for November 2, as it deepens diagnostic offerings across Faecal Dx, Catalyst cardiac and AI workflow ahead of results.
23 Sep at 15:18
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
IDEXX Labs has acquired CoVetAI, marking a strategic step into veterinary workflow intelligence and signaling expansion in its companion animal diagnostics suite.
09 Sep at 15:18
IDEXX Laboratories Sees Institutional Portfolio Shifts as Director Files for Stock Sale
In the past week, IDEXX Laboratories (NASDAQ:IDXX) drew attention from investors as a director filed to sell shares and institutions adjusted their holdings—moves with potential implications for stock dynamics.